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Abstract: The Scandinavian data on pholcodine (PHO) strongly
indicates that there is a biological chain from PHO exposure through
IgE-sensitization to IgE-mediated anaphylaxis to neuromuscular
blocking agents (NMBA). PHO is probably one of the strongest
inducer of an IgE antibody response known. Of individuals taking
PHO in cough medicines, over-the-counter accessibility to large
populations, as many as 20 to 25% may become IgE sensitized. Once
sensitized, PHO re-exposure will booster IgE antibody levels
and IgE by around 100-fold. PHO is monovalent for 2 non–cross-
reacting epitopes the quaternary ammonium ion (QAI), the main
allergenic epitope of NMBA, and a non-QAI epitope. Thus, PHO
most unlikely would initiate an allergic inﬂammatory response. Con-
sequently, IgE sensitization is not revealed by obvious clinical signs,
neither through tests based on IgE-sensitized effector cells. There-
fore, it will escape detection if not assayed serologically. However,
when subjected to general anesthesia, and thus the IgE-sensitized
individual is administered a bivalent NMBA intravenously, the
unrecognized presence of serum IgE antibodies to QAI may increase
the risk of anaphylaxis 200- to 300-fold. Severe damages to patient’s
health can result, and mortality rates of 3 to 10% are reported. The
Scandinavian experience indicates that the chain of events can efﬁ-
ciently be avoided by stopping PHO exposure: Within 1 year, the
prevalence of IgE sensitization to PHO and QAI decreases signiﬁ-
cantly, and after 2 to 3 years, the numbers of reported anaphylactic
reactions decreases equally so.
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In recent years, increasing evidence for a connection betweenthe consumption of pholcodine (PHO), an opioid antitussive,
in cough and cold medicines and IgE-mediated anaphylactic
reactions to neuromuscular blocking agents (NMBA) have
been presented. The issue is, by nature, primarily a challenge
for doctors and researchers within anesthesiology and aller-
gology but not less for regulatory authorities and national
marketing authorization holders. Some are concerned, and
others obviously less disturbed by the warning signals thus
conveyed. The latter position is often promoted by individuals
and ofﬁcial bodies obviously not fully taking into account the
mechanisms by which PHO seems to work. However, the
consequences are to be born by large populations of individ-
uals around the world continuing to consume PHO.
Therefore, it seems appropriate to review published
data on this, in many ways exceptional and devious
connection.
COUGH MEDICINES
Cough and cold medicines in a variety of formulations
and pharmacological combinations, often easily accessible
without prescription [over-the-counter (OTC)], are widely
consumed by most populations world wide. Furthermore,
they are often repeatedly taken because viral and bacterial
infections of the airways are considered close to normal
repetitive afﬂictions appearing in large groups of individuals.
They represent a major body of pharmacological exposure to
populations, and thus, national regulatory authorities are
expected to monitor carefully the effectiveness against the
risks of side effects to the very many exposed.
The effectiveness of available OTC drug combinations
for cough and cold can be questioned. A Cochrane review
including 26 trials in adults and children recently published1
concluded that “There is no good evidence for or against the
effectiveness of OTC medicines in acute cough.” In part, this
rather careful conclusion was arrived at because of consider-
able differences in study characteristics and quality.
PHOLCODINE
A major antitussive constituent in a number of these
remedies is the morphine (MOR) analog PHO. Since the
1960s, PHO has been included as a constituent in an
increasing number of this class of medicines and, thus,
consumed in different degrees in countries around the world.
Following concerns that use of PHO in cough medicines may
put people at the risk of developing anaphylactic reactions to
NMBAs used during surgery, quite recently, the European
Medicines Agency completed a review of the safety and
effectiveness of PHO. According to their recent press
release,2 the Committee for Medicinal Products for Human
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Use of the European Medicines Agency has concluded that
the existing evidence of the risk was weak. Therefore, it
recommended that, “all marketing authorisations for medi-
cines containing pholcodine should be maintained throughout
the European Union (EU).” It further recommended (Table 1)
that, “Patients and health care professionals are reminded that
the beneﬁts of pholcodine continue to outweigh its risks for
the treatment of non-productive cough. No new risks have
been identiﬁed with pholcodine” and “Patients taking phol-
codine-containing medicines can continue to do so, and
should contact their doctor or pharmacist if they have any
questions about their treatment.” However, further studies
were asked for.
In principle, PHO (3-(2-morpholinoethyl)morphine),
originally synthesized in France in the 1950s, is a MOR
molecule with a morpholino side chain (Fig. 1). The modiﬁca-
tion changes the pharmacological mode of action. There is no
depression of respiration, pain relief, and CNS excitation, and it
is void of euphorizing properties and risk of addiction. PHO is
a mild cough suppressant acting directly on the cough center of
the CNS, and it has become a widely used cough medicine in
numerous formulations. Pharmacokinetically, it is much more
slowly eliminated from the body than opioids like codeine, and
the concentration in saliva becomes 3 to 4 times higher than in
plasma,3 properties that might add to its immunogenicity.
There are several manufacturers of PHO on the
international scene. The international sales are monitored by
the United Nations International Narcotics Control Board
(INCB) (www.incb.org). According to their 2008 report, the
global production of PHO amounted totally to 6.7 tons where
France (3.2 tons), the United Kingdom (1.4 tons), and Hun-
gary (768 kg) ranged as the major PHO-producing countries
together accounting for approximately 81% of world produc-
tion. Total registered export was 3.8 tons with the United
Kingdom, Hungary, and Norway as the main exporting coun-
tries. Major importing countries were Hong Kong, Pakistan,
Australia, and Algeria. Global consumption reached 7 tons
equivalent to 140 million sold deﬁned daily doses (S-DDD),
and 96% was consumed in the form of preparations listed in
Schedule III of the UN 1961 Convention On Narcotic Drugs.
PHO-containing cough medicines are available in many
countries around the world and spread over most continents
except the United States. The requirements for PHO by the
nations of the world also are published by the INCB. In Table 2,
we have listed the 29 countries requiring 1 kg or more of PHO
in 2012. However, Table 2 indirectly shows that the absolute
majority of nations are nonconsumers and, thus, they have
decided to meet their inhabitant’s demand for antitussive and
cold medications without the use of PHO.
Important for understanding the connection between
PHO and NMBAs are the structural relationships (Fig. 1). It
has for close to 30 years now been known that the major IgE-
binding epitope of the NMBA contains the quaternary ammo-
nium ion (QAI) or its tertiary variety.4 Our studies have shown
that PHO, and its parent molecule MOR, contains the QAI
epitope, which they share with NMBAs. However, in addi-
tion, another epitope of unknown structure on PHO and MOR,
not present on NMBAs, was found based on ImmunoCAP
(IDD; Thermo Fisher Scientiﬁc, Uppsala, Sweden) inhibition
studies where IgE antibody binding to QAI, that is, suxame-
thonium (SUX), is completely inhibited with PHO and MOR,
but, the binding to PHO and MOR is only partially inhibited
with QAI.5 Thus, important to note, PHO, functionally mono-
valent for the 2 non–cross-reacting IgE-binding structural
sites, can in principle not initiate an allergic reaction toward
itself through cross-binding of IgE antibodies. Therefore, tests
dependent on such cross-binding like skin tests, histamine
release and basophil activation tests, oral provocation tests,
and, not least, intake of cough medicines will come out neg-
ative with PHO in individuals who are IgE sensitized to PHO.
On the other hand, the NMBAs like SUX and rocuronium are
structurally bivalent for the QAI epitope. As such, they appear
functionally as allergens that through the cross-binding of IgE
antibodies on the surfaces of effector cells can induce imme-
diate allergic inﬂammatory responses and enhanced by way of
administration, eventually leading to anaphylaxis.
The main message of this structure–function relation-
ship is that the basic side effect of PHO, namely, its formi-
dable IgE-sensitizing properties, will go largely unnoticed if
only monitored by spontaneous adverse event reporting and
not looking speciﬁcally for IgE antibodies. Only occasionally
will it become clinically manifest like through an anaphylac-
tic reaction to a NMBA, through the referral of patients to
allergy clinics for elevated IgE and IgE antibodies of unclear
etiology and questionable clinical consequence, or through
the odd patient with severe allergic bronchial asthma who is
excluded from the treatment option with anti-IgE because the
IgE apparently unexplained has become too high and out of
range for the capacity of this treatments.
IgE SENSITIZATION
Primary Sensitization
Our present view on the connection among PHO
exposure, IgE-sensitization, and anaphylaxis is summarized
in Figure 2. There does not exist randomized controlled trials
to evidently document the primary IgE-sensitizing potential
of PHO, that is, how many of those exposed develop IgE
antibodies to PHO. For many years now, such study protocols
would probably not pass research ethic evaluations based on
present knowledge, at least not in Scandinavia.
However, a considerable body of data supports that
primary sensitization by PHO really takes place. Seroepide-
miological studies comparing Norway and Sweden, at the
TABLE 1. Main Conclusions From the Recent Review on the
Safety And Effectiveness of PHO by the European Medicines
Agency’s Committee for Medicinal Products for Human Use2
1 The beneﬁts of pholcodine continue to outweigh its
risks
2 No new risks have been identiﬁed with pholcodine
3 Although a cross-sensitization between pholcodine
and NMBA is biologically plausible, the available
data are weak and not fully consistent
4 Patients taking pholcodine-containing medicines can
continue to do so
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time of study representing high–PHO-consuming and non–
PHO-consuming countries, respectively, have shown that in
Norway, 6% of blood donors and 11% of those with allergy
were IgE sensitized to PHO, whereas in Sweden, not one
single sensitized individual was found.5
PHO was withdrawn from the Norwegian market by the
marketing authorization holder in March 2007 because of the
suspected link between national PHO consumption and IgE
sensitization on one hand, and the number of reported cases of
NMBA anaphylaxis on the other. However, the national drug
authorities were also much concerned about the remarkable
effect of PHO on the control mechanisms of IgE production
(see below). As a result, the prevalence of sera IgE sensitized
to PHO among those with allergy decreased from 11% to
2.7% in 2010, that is, after 3 years without PHO available
OTC or by prescription6 but, still for some time, at the indi-
vidual’s “drug store” at home. Also the number of anaphylaxis
decreased signiﬁcantly. Thus, the decrease in exposure in Nor-
way coincided with a signiﬁcant decrease in the prevalence of
IgE sensitization and reported cases of anaphylaxis. The same
had been observed in a retrospective study from Sweden.7
An international multicenter study comparing consum-
ing and nonconsuming countries, found a signiﬁcant associ-
ation (P , 0.03) between the national consumptions of PHO,
according to the INCB, and the percentages of sera with IgE
antibodies to PHO using Phadiatop (IDD; Thermo Fisher Sci-
entiﬁc) positive allergics as screening populations.8 For 2
countries in this study, the Netherlands and the United States,
the results were interesting because both showed IgE sensiti-
zation to PHO but neither had known PHO-containing drugs
on their markets. This could either mean PHO sensitization
through unofﬁcial drugs or other means, or mean that other
substances than PHO also could induce IgE antibodies. We
found it a highly interesting challenge to look for such, prob-
ably QAI-containing, substances in the environment. There
are indeed many candidates among the daily life chemicals
and drugs, but we have after considerable efforts yet not been
able to ﬁnd any with sensitizing properties.9 However, others
argument that this failure discounts the PHO hypothesis.2,10
The former Norwegian marketing authorization holder
estimated that approximately 40% of the population was exposed
to PHO through their products. According to the published
sensitization data,5 this could indicate that as many as 1 in 4 to 5
of exposed individuals may develop IgE antibodies to PHO.
At the time when PHO was on the Norwegian market,
one observed that those with allergy with IgE levels between
1000 and 5000 kU/L and more than 5000 kU/L were in
approximately 30 % and 75 %, respectively, associated with
IgE-sensitization to PHO.6 Consequently, a major part of
patients presenting highly elevated IgE could be correctly
diagnosed, and, better still, treated by seeing to that PHO
exposure ceased and thereafter monitoring levels toward nor-
malization. Both reported data and unpublished observations
showed that in most individuals, IgE antibodies decreased to
less than 0.35 kUA/L and IgE to pre-exposure levels within 1
to 2 years; however, some individuals retained highly ele-
vated levels for many years.
Booster on Re-exposure
When an IgE-sensitized individual is exposed to an
allergen, a booster of the IgE antibody production is expected
to take place. However, in sharp contrast to the 2- to 3-fold
FIGURE 1. Schematic
representation of morphine,
pholcodine, and, the NMBA,
suxamethonium. The IgE-binding
epitopes, the quaternary/tertiary
ammonium epitopes are encircled.
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increase in IgE antibodies to timothy seen after the timothy
grass pollen season in timothy allergic individuals, one third
of the recommended daily dose of PHO taken during 1 week
resulted in a close to 100-fold increase in serum levels of IgE
antibodies to PHO and QAI within 3 weeks and equally so of
IgE in all of the 13 sensitized patients exposed.9,11 No effect
was seen by codeine, noscapine, and guaifenesin in the 8 IgE-
sensitized patients or even by PHO in the 2 nonsensitized
controls. In addition, serum IgE antibodies to common aller-
gens like house dust mite and cat dander that could not be
detected (ie, ,0.1 kUA/L) before PHO exposure could reach
levels in the order of 3 to 5 kUA/L after exposure, indicating
a polyclonal response.
The mechanisms by which PHO activates IgE synthesis
are not known, but the exposure results indicate that the
“tail,” the morpholino side chain, added to the MOR molecule
(Fig. 1) to create PHO might be involved. The results further
indicate that PHO in an individual IgE sensitized to PHO has
a most pronounced effect on the control mechanism for IgE
production. As a result, the number of individuals with high
levels of IgE antibody to QAI to be at risk for anaphylaxis to
NMBA will increase. Similarly, it is theoretically possible
that in atopic individuals, the risk for and severity of an
IgE-mediated allergic reaction might increase, and equally
so the number of blood donors whose blood plasma could
passively transfer a temporary allergy to the recipient.12
The effect on the mechanisms controlling the IgE
production was remarkable. Such an IgE booster phenome-
non has previously been seen only in the graft-versus-host
disease during rejection of a bone marrow transplant13 but
also in angioblastic lymphadenopathy upon cytostatic treat-
ment. The complete clinical importance of this impact is not
known, but we strongly suggest that such a serious adverse
drug effect is avoided, especially because there are several
alternative drugs available OTC for the treatment of mild
nonproductive cough.
Ratio of QAI to Non-QAI Specificities
According to the structure–function relationship
described, the ratio of IgE antibodies to PHO with the 2
speciﬁcities, the QAI and the non-QAI epitope, respectively,
seem to vary considerably from less than 1/10 in blood donors
to approximately 1/3 in those with allergy.6
A diagnostic consequence of this relationship may be
that when MOR is used to screen for IgE antibodies to
TABLE 2. Overview of Official World Requirements for PHO
as Given by the United Nations INCB as per January 2012
Continent Country
2012 Ofﬁcial PHO
Requirements (kg)
Africa Algeria 2500
Morocco 106
Nigeria 20
South Africa 215
Tunisia 22
Zimbabwe 3
United States
Asia Afghanistan 100
China 410
Hong Kong 2000
Egypt 200
Malaysia 200
Nepal 7
Pakistan 3206
Singapore 15
Europe Albania 1
Belgium 230
Bosnia and Herzegovina 28
France 4050
Ireland 300
Italy 300
Macedonia 150
Netherlands 50
Poland 47
Slovenia 9
Spain 5
Switzerland 10
United Kingdom 1000
Oceania Australia 850
New Zealand 35
N ¼ 29
The requirements are reported in kilograms, and only countries requiring 1 kg or
more are listed.
FIGURE 2. Relationship between pholcodine exposure, IgE-
sensitization, and quaternary/tertiary ammonium epitopes (QAI)
and estimated risk of IgE-mediated anaphylaxis when receiving
suxamethonium during induction of general anesthesia in
Norway. IgEab, is the abbreviation of IgE antibodies. The
relationships depicted apply for the years before 2007 when
pholcodine (PHO) was taken off the Norwegian market. PHO
exposure is given as estimated by the former marketing
authorization holder in Norway. Percentage IgE-sensitized to
PHO and the relative distribution of IgE specificities to the QAI
and the non-QAI epitopes of PHO, respectively, is taken from
studies by Florvaag et al.5,6 The risk estimates for anaphylaxis
during general anesthesia with NMBAs for the general
population and individuals IgE sensitized to the QAI epitope
before anesthesia with suxamethonium are taken from Harper
et al.22 Risk is given as the ratio of anaphylactic reactions to
number of uneventful general anesthesias using a NMBA.
Approximate number of populations in millions is given in italics.
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NMBA (ie, the QAI-containing epitope),14,15 it is possible
that the majority of IgE antibodies bind the non-QAI and
not the QAI epitope. Indeed, we have shown that before
PHO withdrawal, 5% of blood donors were IgE sensitized
($0.35 kUA/L) to MOR but only 0.4% to SUX (ie, the
QAI epitope). In individuals with allergy, the prevalences
were 10% and 3.4%, respectively.5,6 However, it is possible
that the assay for IgE antibodies to SUX is not sensitive
enough.16 Also, it cannot be excluded that SUX also is pre-
sented in vivo with a carrier protein resulting in a modiﬁed
allergenic epitope that stimulates IgE antibodies with an
altered speciﬁcity not detected by the SUX available for testing
in vitro like Patent Blue V.17
IgE-MEDIATED ANAPHYLAXIS TO NMBA
During the past 3 to 4 decades, anaphylactic reactions
during general anesthesia seem gradually to have increased in
frequency with reported prevalences in the order of 1/5000 to
1/100,000.14,15,18 However, during this period, the main sci-
entiﬁc focus and bulk of publications on anesthetic anaphy-
laxis originate from a mere handful of countries. Some of
these have additionally found it necessary to establish stan-
dardized national reporting and diagnostic routines and aller-
goanesthesiological follow-up units to better handle the
challenge.16,18–21 But from the majority of the nations in
the world, there have been none or few published reports
indicating that in most countries, NMBA-related anaphylaxis
is regarded as a clinical problem of limited magnitude.
France, Australia, the United Kingdom, and Norway are the
countries with high scientiﬁc focus on this topic. All of them,
except Norway after PHO withdrawal in 2007, are together
with a few others ﬁguring on the deﬁnite upper end of the
INCB list of PHO consumers (Table 2), whereas the large
majority of nations remain non-consumers.
In most of the affected countries, but not all, NMBAs
are blamed to cause the majority of reactions.22,23 Although
mainly IgE mediated, most events take place without prior
exposure to NMBAs, thus strongly indicating that primary
IgE sensitization has taken place by exposure to other envi-
ronmental factors than anesthetic drugs. The less common
reactions reported of atracurium might differ in this respect
because they seem to occur in multioperated patients without
IgE antibodies to QAI.24
From Sweden and Norway, 2 interventional studies
have been published, 1 retrospective and 1 prospective,
showing that removing exposure to PHO within few years
signiﬁcantly decreases IgE sensitization and prevalences of
reported anaphylactic reactions to NMBAs.6,7
The key points of the Scandinavian PHO experiences
are therefore as follows: First, and with caution because of
the small number of individuals studied, Norwegian esti-
mates indicate that if an individual, unknowingly IgE
sensitized to the QAI-epitope (e.g. SUX) through PHO
exposure, is subjected to the induction of general anesthesia
with SUX intravenously, the risk of an IgE-mediated
anaphylactic reaction is increased between 200 and 300
times (ie, from 1/5200 as estimated for the general
population to 1/20).16 Second, if PHO exposure is stopped,
ﬁrst IgE sensitization and then reports of NMBA-related
anaphylaxis goes down signiﬁcantly as reported in studies
from Sweden and Norway.6,7 Furthermore, in Denmark, an
unexposed country, anaphylaxis to NMBAs is indeed very
rarely diagnosed.21
CONCLUSIONS
PHO and NMBA share the major allergenic epitope
QAI. The direct effects of PHO on IgE synthesis resulting in
a remarkable polyclonal increase in IgE are well documented.
However, the mode of action and eventual predisposing
individual factors are unknown. The morpholino side chain
probably plays a role. An increasing body of evidence
suggests an association among PHO consumption, IgE
sensitization, and NMBA-induced anaphylaxis. When regu-
latory authorities assess the raised pharmacovigilance
concerns about PHO exposure, the primary step, IgE
sensitization, needs to be addressed serologically.25 This rep-
resents direct and reliable monitoring. Counting clinical
events down the far end of the biological chain of events,
like NMBA-related anaphylaxis, is a much more indirect
approach because other disease modifying factors may play
roles. In addition, it takes time and is hampered with well-
accepted issues like statistics on rare events and validity of
spontaneous reporting systems.
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